Literature DB >> 16022187

Strategies to optimize brain penetration in drug discovery.

Xingrong Liu1, Cuiping Chen.   

Abstract

The kinetics of brain penetration has two components, extent and rate. Achieving a high extent of brain penetration is an important focus for central nervous system (CNS) drug discovery. Optimal brain penetration can be achieved by reducing efflux transport at the blood-brain barrier (BBB), and it is critical to ensure that a high total brain/plasma ratio (the most commonly used parameter for measuring brain penetration) is due to efflux transport activity at the BBB and not related to high non-specific brain tissue binding or low plasma binding. Rapid brain penetration is essential for those drugs that require fast onset of action in the CNS. This can be achieved by increasing passive permeability and reducing brain tissue binding.

Mesh:

Substances:

Year:  2005        PMID: 16022187

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  15 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 2.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 3.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Authors:  Nithya Srinivas; Kaitlyn Maffuid; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

5.  Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Authors:  Rong Zhao; J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2009-04-22       Impact factor: 4.200

Review 6.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 7.  In vitro, in vivo and in silico models of drug distribution into the brain.

Authors:  Scott G Summerfield; Kelly C Dong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

8.  Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier.

Authors:  Xing-xing Diao; Kan Zhong; Xiu-li Li; Da-fang Zhong; Xiao-yan Chen
Journal:  Acta Pharmacol Sin       Date:  2015-11-16       Impact factor: 6.150

9.  Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.

Authors:  Rong Zhao; J Cory Kalvass; Souzan B Yanni; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2008-12-29       Impact factor: 3.922

10.  A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).

Authors:  Ronit Shaltiel-Karyo; Moran Frenkel-Pinter; Edward Rockenstein; Christina Patrick; Michal Levy-Sakin; Abigail Schiller; Nirit Egoz-Matia; Eliezer Masliah; Daniel Segal; Ehud Gazit
Journal:  J Biol Chem       Date:  2013-05-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.